Search research articles
Contact Us
Filters
Showing results (321-330 of 332) with videos related to
Page
of 34
Sort By:
ESMO Open
|
April 15, 2022
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study
M Mark, S Rusakiewicz, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 23, 2020
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
Y Metaxas, M Früh, E I Eboulet, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 3, 2023
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
A Schuler, J Huser, S Schmid, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
July 19, 2012
Exposure to microbial agents in house dust and wheezing, atopic dermatitis and atopic sensitization in early childhood: a birth cohort study in rural areas
A M Karvonen, A Hyvärinen, U Gehring, et al.
ESMO Open
|
November 11, 2025
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
L Frehner, S Schär, S Hayoz, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 19, 2024
Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort
Y Li, M Wong, L Zhan, et al.
ESMO Open
|
July 13, 2023
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
D König, S Savic Prince, S Hayoz, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine
|
April 28, 2004
Intercomparison experiments of systems for the measurement of xenon radionuclides in the atmosphere
M Auer, A Axelsson, X Blanchard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2025
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial
P S Schmid, H L McArthur, J Cortés, et al.
Allergy
|
January 18, 2006
European birth cohort studies on asthma and atopic diseases: I. Comparison of study designs -- a GALEN initiative
T Keil, M Kulig, A Simpson, et al.
Page
of 34
Search research articles
Search
Showing results (321-330 of 332) with videos related to
Sort By:
Page
of 34
ESMO Open
|
April 15, 2022
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study
M Mark, S Rusakiewicz, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 23, 2020
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
Y Metaxas, M Früh, E I Eboulet, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 3, 2023
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
A Schuler, J Huser, S Schmid, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
July 19, 2012
Exposure to microbial agents in house dust and wheezing, atopic dermatitis and atopic sensitization in early childhood: a birth cohort study in rural areas
A M Karvonen, A Hyvärinen, U Gehring, et al.
ESMO Open
|
November 11, 2025
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
L Frehner, S Schär, S Hayoz, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 19, 2024
Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort
Y Li, M Wong, L Zhan, et al.
ESMO Open
|
July 13, 2023
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
D König, S Savic Prince, S Hayoz, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine
|
April 28, 2004
Intercomparison experiments of systems for the measurement of xenon radionuclides in the atmosphere
M Auer, A Axelsson, X Blanchard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2025
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial
P S Schmid, H L McArthur, J Cortés, et al.
Allergy
|
January 18, 2006
European birth cohort studies on asthma and atopic diseases: I. Comparison of study designs -- a GALEN initiative
T Keil, M Kulig, A Simpson, et al.
Page
of 34